ArticleObesity pillars2026
Fat and lean mass changes during incretin-based therapy with structured exercise and nutritional support: A retrospective real-world pilot study.
Article in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Incretin-based therapies are highly effective for weight reduction, but changes in lean mass during treatment remain a clinical concern. This study evaluated changes in fat mass and lean mass in individuals receiving structured exercise and nutritional support during incretin-based therapies. Methods: In this single-center retrospective observational chart-review study, 11 adults who underwent 9-12 months of incretin-based therapy and were offered a program providing supervised exercise and individualized nutritional support were analyzed. No control group was included. Treatments included glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor co-agonists. Body composition was assessed using dual-energy X-ray absorptiometry (DXA). Data were assessed for parametric assumptions, and pre- and post-intervention comparisons were performed using paired-samples t tests. Results: Significant reductions were observed in body weight (mean change: -4.99 kg [95% CI: -7.65 to -2.34]; p = 0.002) and fat mass (-4.37 kg [95% CI: 6.36 to -2.39]; p < 0.001), corresponding to a mean total weight reduction of 4.71% and a mean fat mass reduction of 11.06% Conclusion: Incretin-based therapy delivered within a structured exercise and nutritional support program was associated with fat-dominant weight reduction without a statistically significant change in lean mass. These findings are hypothesis-generating and warrant confirmation in adequately powered prospective controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.